Adenosine, an intercellular messenger that is a product of the metabolism of ATP, plays a major role in neuronal and vascular responses of the retina to alterations in oxygen delivery. Significant changes in adenosine concentration have been measured in the retina during both ischemia and during the subsequent reperfusion period which result in important, but complex, functional effects. Adenosine A1 receptor stimulation produces a protective effect during ischemia, whereas overstimulation of the A2a receptor has deleterious effects. The mechanisms underlying these findings have not been completely determined, but most likely are the result of alterations in excitotoxicity, gene expression, and blood flow. Paradoxically, prolonged increases in adenosine concentration may be injurious to the retina, a consequence of superoxide radical formation secondary to adenosine catabolism. Adenosine is a critical mediator of blood flow changes in response to ischemia. It is a significant component of the retina's compensatory hyperemic response to ischemia, hypoxia, and hypoglycemia. Increasing endogenous adenosine concentrations may be useful in ameliorating post-ischemic hypoperfusion. Overall, current evidence suggests that adenosine is a vital component of the endogenous retinal response to substrate deprivation. Additionally, in vitro studies provide strong evidence that adenosine is a mediator of the formation and effects of vascular endothelial growth factor, which in turn promotes neovascularization. Finally, the ability of the retina to develop an ischemia-tolerant state by ischemic preconditioning is an intriguing phenomenon that reveals yet another essential role for adenosine in the retina's endogenous response to ischemia. The experimental results described in this review suggest that continued investigation into the role of adenosine in the retina may lead to important clinical applications for adenosine-based therapies that could decrease the incidence of retinal damage in ischemic vasculopathies such as diabetes, glaucoma, and retinal vascular occlusion.
Introduction
Adenosine, a purine nucleoside product of the metabolism of high-energy phosphates, is a significant intercellular mediator in the central nervous system, a role first recognized over 40 years ago (see Williams & Burnstock, 1997, for review) . Important roles in which adenosine serves in a regulatory or modulatory capacity include: neurotransmission, blood flow, inflammation, pain, and the endogenous response to ischemia (Phillis, 1989; Cronstein, 1994; Rudolphi & Schubert, 1997) .
Three major receptor classes for adenosine have been characterized: these are designated as A1, A2, and A3 adenosine receptors (Jacobson, Galen & Williams, 1992) . The receptors are G-protein linked, and subserve a variety of different effects upon adenylyl cyclase, ion channels, and phospholipase C (Table 1) .
A growing body of evidence indicates that adenosine is an important intercellular mediator in the retina. It is widely, although heterogeneously, distributed throughout the retina of various species (Blazynski & Perez, 1991) . A1 receptor binding sites occur mostly in the inner retina, whereas A2 receptor binding sites are predominantly found in the outer retina. The highest adenosine immunoreactivity is present in the ganglion cell, inner plexiform, and inner nuclear layers (Braas, Zarbin & Snyder, 1987) . This distribution of adenosine suggests that it is well positioned to serve as a mediator of important physiological and pathophysiological processes in the retina. Because of its diverse roles in neurotransmission and the control of tissue blood flow, adenosine appears to be of particular importance in the pathophysiology of ischemic disease, but much remains to be learned about its ubiquitous effects. Results of recent experiments from several laboratories, including our own, are confirming the physiologic and pathophysiologic significance of adenosine in animal models of retinal vascular disease, which is related to adenosine's ability to regulate and influence tissue perfusion and metabolism. This review summarizes our current understanding of the role of adenosine in normal retinal function, and its unique roles in the pathophysiology of ischemic retinal vascular disease.
Retinal vascular disease: pathophysiology

Most cases of visual loss and blindness in the United
States are caused by diseases that are ultimately secondary to retinal ischemia. Retinal ischemia can occur from direct decreases in blood supply as a result of retinal arterial or venous occlusion, or from acute and chronic tissue hypoxia. Glaucoma, atherosclerosis, and the ocular complications of systemic disorders such as diabetes mellitus also lead to retinal ischemia. The neovascularization that follows is a common feature of many chronic eye diseases and is the major cause of blindness in the world (Miller, Adamis & Aiello, 1997) . This neovascularization is thought to occur secondary to ischemia-or hypoxia-induced stimulation of diffusible growth factors (e.g., vascular endothelial growth factor, VEGF) which promote neovascularization of the retina and optic nerve head. However, the pathways responsible for increased production of these factors in response to acute or chronic hypoxia/ischemia are incompletely understood. Depending on the character of the ischemic stimulus, the purine nucleoside adenosine appears to serve at least two key roles: as an intercellular signaling factor promoting the neovascularization process after chronic hypoxia or ischemia, and as an endogenous protective factor capable of protecting the retina from acute ischemia.
Biochemistry and gene expression in retinal ischemic disorders
Depriving cells in the central nervous system of oxygen results in a number of critical biochemical alterations. Among these are the breakdown of ATP to adenosine, and the enhanced release from inside the cell of excitatory amino acids (glutamate, aspartate) which bind to specific receptors (Choi, 1995) , initiating a complex series of injurious reactions known as excitotoxicity. Strong support for a parallel mechanism in the retina is suggested by a number of different studies. Elevated extracellular glutamate concentrations are found in the in vivo rat retina during ischemia (Louzada, Dias, Santos, Lachat, Bradford & CoutinhoNetto, 1992) and in the vitreous of monkeys and humans with glaucoma (Dreyer, Zurakowski, Schumer, Podos & Lipton, 1996) . Moreover, glutamate receptor antagonists attenuate ischemic injury in vitro and in vivo (Yoon & Marmor, 1989; Zeevalk & Nicklas, 1990; Mosinger, Price, Bai, Xiao, Wozniak & Olney, 1991) .
However, treatment with excitatory amino acid antagonists may not be sufficient to effectively interrupt the excitotoxic pathway (Mosinger, Price, Bai, Xiao, Wozniak & Olney, 1991; Lipton & Rosenberg, 1994; Chen, Harris, Brown, Howe, Surmeier & Reiner, 1995; Dreyer et al., 1996) . In fact, ischemia triggers multiple biochemical cascades, including alterations in genetic expression, that may injure or, alternately, protect retinal cells. Therefore, examination of additional nonglutamatergic mechanisms that may be involved in the pathophysiology of retinal ischemic damage has assumed a growing interest and significance.
In the brain, ischemia was found to increase the expression of immediate early gene products, e.g., c-fos, heat shock protein, and amyloid precursor protein, among others (Atkins, Liu & Hsu, 1996; Koistinaho & Hokfelt, 1997) . Ischemia-induced alterations in gene expression have also been documented in the retina. Specifically, increased activity of the tyrosine kinase pathway was found in the rat retina after ischemia and reperfusion. This activation of signal proteins could play a role in ischemia-induced cellular proliferation (Hayashi, Koroma, Imai & de Juan, 1996) , although it is not yet clear which of these mechanisms are injurious or represent possibly an endogenous protective response to ischemia. Additionally, mRNA for VEGF was increased in retinal capillary endothelial cells and pericytes exposed to hypoxia, suggesting a pathogenic Stiles (1997) . Fig. 1 . Immunochemical staining for adenosine in rat (A) and guinea pig (B) retinae, showing the distribution of adenosine in the retina. Retinal 8 mm thick paraffin sections were stained using specific adenosine antisera. Symbols: gc, ganglion cell layer; ip, inner plexiform layer; in, inner nuclear layer; op, outer plexiform layer; on, outer nuclear layer; os, outer segments of the photoreceptor cell layer. Reprinted with permission from Braas et al. (1987) .
mechanism for vasoproliferative diseases (Takagi, King, Ferrara & Aiello, 1996a ) (see Section 9.3). These and related findings support the theory that changes in gene expression play a significant role in the pathogenesis of ischemic disorders in the retina. Presently, it remains largely unknown which signals initiate changes in gene expression following ischemia. However, adenosine may serve this role under some conditions (Asaoka, Nakamura, Yoshida & Nishizuka, 1992; Kontny, Kvanta & Fredholm, 1992; Kvanta & Fredholm, 1993) . For example, in brain it is theorized that adenosine may stimulate the release of neurotrophic factors such as nerve growth factor, which could be neuroprotective (Rudolphi & Schubert, 1997) . Adenosine stimulated the production of VEGF in retinal endothelial cells in vitro (Takagi, King, Robinson, Ferrara & Aiello, 1996b) . Our most recent studies indicate that adenosine is essential for the production of the endogenous retinal protective response caused by ischemic preconditioning (IPC), i.e., the induction of retinal tolerance to ischemia that occurs following a brief, non-damaging ischemic insult (Roth, Li, Rosenbaum, Gupta, Goldstein, Maxwell et al., 1998) . IPC protection was also shown to require de novo protein synthesis. These sets of findings suggest that adenosine may be a critical signal in the control of gene expression after retinal ischemia (Li & Roth, in press ).
Adenosine localization in the retina
During resting conditions, endogenous purines in the retina exist primarily in the form of ATP (70%) with only 2% existing as adenosine (Perez, Ehinger, . Low power photomicrographs of retinal sections after in situ hybridization with antisense oligonucleotide probes to the adenosine A1 and A2a receptors, demonstrating the distribution of the receptor mRNA in the rat retina. Left panel is a dark field photomicrograph of A1 receptor mRNA distribution. The right panel is a bright field photomicrograph of A2a receptor mRNA distribution. Symbols: gc, ganglion cell layer; in, inner nuclear layer; on, outer nuclear layer; ch, choriocapillaris. The left panel shows that A1 receptor mRNA is present in the ganglion cell, inner nuclear, and outer nuclear layers. The right panel indicates that A2a receptors are found in the inner and outer retina. Adapted with permission of Academic Press, from Kvanta et al. (1997). strom & Fredholm, 1986) . Endogenous adenosine is widely distributed within the retina, and its localization shows similarities in distribution in a variety of species. In the rat, guinea pig ( Fig. 1) , monkey, and human retinae, nearly all of the adenosine immunoreactivity was found in the ganglion cell, inner plexiform, and inner nuclear layers (Braas et al., 1987; Blazynski, Mosinger & Cohen, 1989a) . A small population of photoreceptor cells contained adenosine (Braas et al., 1987) . In the cat, adenosine was autoradiographically localized to the ganglion cell and inner nuclear layers, particularly over cell bodies in the vitreal half, likely representing amacrine cells (Blazynski, Cohen, Fruh & Niemeyer, 1989b) .
Adenosine receptors are localized generally to many of the same retinal layers as endogenous adenosine. Autoradiographic studies in rat retina using the A1 selective ligands L-[ 3 H]-phenylisopropyladenosine (PIA) and [ 125 I]-hydroxyphenylisopropyladenosine localized the A1 receptor to the nerve fiber, ganglion cell, and inner plexiform layer as well as to the inner portion of the inner nuclear layer (Braas et al., 1987) . The monkey retina showed A1 receptors distributed from the nerve fiber to the outer plexiform layers, while the human retina showed widespread binding of the A1 receptor ligand throughout the entire retina. However, A1 receptors seemed to be most plentiful in the nerve fiber layer of the human inner retina (Braas et al., 1987) . Labeling of rabbit and mouse retinas with tritiated PIA, cyclopentyladenosine (CPA), and N-ethylcarboxamidoadenosine (NECA) revealed that A1 receptors were limited to the inner retina, most notably over the inner plexiform layer, whereas A2 receptors were localized to the retinal pigment epithelium (RPE) and both the outer and inner segments of photoreceptors (Blazynski & McIntosh, 1992) . Adenylate cyclase assays and radioligand binding studies on bovine retina preparations using NECA in the presence of the A1 selective agonist CPA revealed two classes of A2 binding sites: a high affinity A2a receptor and a low affinity A2b receptor.
Adenosine receptors were recently localized in the rat eye by in situ hybridization with 35 S-labeled sense and antisense probes (Kvanta, Seregard, Sejersen, Kull & Fredholm, 1997) . In general, for the A1 receptor, there was agreement between localization of the receptor transcript and the translational product described in earlier studies. A1 mRNA was found particularly in the ganglion cells, some of the inner nuclear cells, and in the ciliary bodies (Fig. 2) . No A1 mRNA was found in the outer nuclear layer. A2a mRNA was found in the ganglion cell, inner nuclear, and outer nuclear layers, and in the choriocapillaris (Fig. 2) . While the A3 receptor has been described in other tissues including testis, kidney, lung, heart, and, to a lesser degree, brain, no significant expression of A3 mRNA was found in rat eye (Linden, Taylor, Robeva, Tucker, Stehle, Rivkees et al., 1993) . While 3 H-NECA-binding studies localized A2 receptors to human RPE (Friedman, Hackett, Linden & Campochiaro, 1989) , no A2a or A2b mRNA could be found in RPE (Kvanta et al., 1997) . However, human RPE cells in culture accumulated cyclic AMP in response to the non-selective A2 adenosine agonist NECA, suggesting the presence of adenosine A2 receptors on these cells (Friedman et al., 1989) . Moreover, since PIA and CPA, both relatively selective A1 receptor agonists, had no effect on isoproterenol-stimulated cyclic AMP levels in this tissue, the latter authors concluded that RPE cells do not contain A1 receptors typically linked to decreases in cyclic AMP formation. Divergent findings between studies using the subtypespecific antisense probes versus autoradiography may be partly explained by non-specific binding of 3 H-NECA to the A1, A2a, and A2b receptors. Alternatively, the results of in situ hybridization for mRNA may differ because the translated receptor product is translocated, and therefore localization of the mRNA may differ from that of the receptor itself.
In summary, adenosine's wide distribution throughout the retina has been documented in a diverse number of species. Found predominantly in the inner retina, it is also present in the RPE and in photoreceptors. The A1 receptor occurs mostly within the inner retina, while the A2 predominates within the outer retina. There is, as yet, no evidence for A3 receptor activity in the retina. The localization of adenosine receptor mRNA transcripts generally correlates well with autoradiographic localization of the A1, but not the A2 receptors. This widespread distribution of adenosine and its receptors suggests that adenosine is well positioned to serve as a mediator of important physiological and pathophysiological processes in the retina.
Molecular biology and pharmacology of adenosine receptors
The physiological actions of adenosine result from its binding to specific receptors, leading to the activation of signal transduction systems. All of the adenosine receptors have been cloned, although to date, the genomic structure is available only for the A1 receptor. The adenosine receptor systems interact with a wide variety of G-proteins, including Gi, Go, Gq, and Gs (Table 1) .
The A1 receptor was cloned from rat, human, bovine, and rabbit. The clones and the expressed receptor protein are similar between the various species. The A1 receptor is about 326 amino acids, or 36 -37 kDa. Mutations in His-274 and His-251 result in loss of agonist and antagonist binding. Multiple regions are responsible for the binding of receptor agonists and antagonists; using chimeric receptor constructs, transmembrane domains 5, 6, and 7 were shown to be important for the binding of agonists and antagonists (Stiles, 1997) . In the brain, A1 receptors couple to the G-proteins Gi and Gs and inhibit adenylyl cyclase. The A1 receptor is primarily involved in the inhibitory actions of adenosine. These include depression of the membrane potential (via increased K + and Cl − conductance), decreased calcium influx, and depression of neurotransmitter release, including, e.g., glutamate, and dopamine (Crosson, DeBenedetto & Gidday, 1994) . These effects result in decreased neuronal excitability and metabolism (Schubert, Rudolphi, Fredholm & Nakamura, 1994; Rudolphi & Schubert, 1997) , and can be considered neuroprotective in the setting of tissue ischemia.
The A2a receptor was cloned from a canine, rat, and human. It is 410-412 amino acids in size, or about 45 kDa, comparable in size to the A1 receptor (Stiles, 1997) . Mutations in similar regions to those of the A1 receptor also lead to loss of agonist and antagonist binding. However, there are at present few specific ligands for studying the structure of the A2a receptor. A2a (high affinity) and A2b (low affinity) receptors are Gs-coupled and are traditionally thought to activate adenylyl cyclase (Schubert et al., 1994) . Adenosine relaxes vascular smooth muscle by an A2-receptor-mediated mechanism, thereby promoting increases in tissue perfusion. Recent evidence indicates that, in retina, these vasodilatory effects of adenosine are mediated by A2 receptors linked in a unique way to K + ATP channels (Gidday, Maceren, Shah, Meier & Zhu, 1996) . A2 receptors may also be important in adenosine's neuromodulatory effects that occur in concert with A1 receptors (Sebastiao & Ribeiro, 1996) . There is also evidence from retinal slices that adenosine promotes glycogenolysis via an A2 receptor on Muller cells (Osborne, 1989) . This would represent yet another way adenosine promotes an increase in the supply/demand ratio for metabolic substrates in the retina. Stimulation of the A2a receptor decreases superoxide release from activated neutrophils and inhibits platelet aggregation (Cronstein, 1994) , which are documented anti-inflammatory actions in vitro, not yet demonstrated to be of importance in the retinal response to ischemia. The role of the A2b receptor has not yet been clearly established.
The A3 receptor was cloned from human, rat, and sheep. It is about 320 amino acids in size, and 40-50% of these are identical to the structures of the A1 and A2 receptors. This receptor has low affinity for alkylxanthine antagonists like theophylline and caffeine, which are classic antagonists at the A1 and A2 receptors. Recently, the agonist IB-MECA was developed which binds to the A3 receptor, although not specifically (Linden, 1994) . Specific antagonists have also recently been described (Jacobson, 1998) . The A3 receptor inhibits adenylyl cyclase and activates phospholipase C (Table 1) (Linden, 1994) . Stimulation of the A3 receptor also enhances Ca 2 + mobilization and inhibits TNFa (Linden et al., 1993; Linden, 1994) . Considerably higher adenosine concentrations than would be active at A1 and A2 receptors, likely generated during ischemia, are required to activate the A3 receptor (Ki=1 mM versus 10 and 30 nM for A1 and A2a in the rat, respectively). In the cerebral cortex in gerbils, the acute administration of an A3 receptor antagonist or the chronic administration of an A3 receptor agonist protected against damage from global ischemia, suggesting possible therapeutic approaches involving the A3 receptor (Jacobson, 1998) . However, further studies are necessary to precisely define the role of the A3 receptor in ischemic retina.
Adenosine metabolism
While adenosine formation and metabolism have been studied in detail in organs such as skeletal muscle, brain, and heart, relatively little data currently exist concerning these processes in the retina. Ganglion and inner nuclear layer cells accumulated adenosine, pro- cesses blocked by the purine nucleoside transport inhibitor nitrobenzylthioinosine (NBTI) (Blazynski, 1991) . From studies in other organs, it has been found that adenosine may be formed both intra-and extracellularly ( Fig. 3 ), but intracellular metabolism of ATP by the action of 5%-nucleotidase, and metabolism of Sadenosyl-homocysteine by a hydrolase enzyme (Zhang, Franklin & Murray, 1993) predominate. This latter pathway contributes significantly to adenosine formation in the heart (Deussen, Lloyd & Schrader, 1989) and during ischemic conditions in the brain (Latini, Corsi, Pedata & Pepeu, 1996) . Once formed, intracellular adenosine must be transported out of the cell in order to exert its effects upon cell surface receptors. Adenosine transport out of the cell is facilitated and bidirectional (Schubert et al., 1994) . Extracellular adenosine is believed to originate from membrane bound 5%-nucleotidase (ecto-5%-N)-catalyzed breakdown of 5%-AMP. This mechanism of adenosine formation can be differentiated from intracellular adenosine formation using specific antibodies to and inhibitors of ecto-5%-N (Smolenski, Kochan, McDouall, Page, Seymour & Yacoub, 1994) . Since AMP is formed from the breakdown of ATP, adenosine formation is closely linked to cellular energy state, and can thus serve as a signal to increase the energy supply/demand balance primarily by affecting cellular metabolic rate and tissue perfusion.
Adenosine's metabolites may also have significant physiological and pathological effects. The levels of adenosine available for these effects are determined by a number of factors, which include its rate of production, transport, and metabolism. Degradation of adenosine is catalyzed by adenosine deaminase (ADA) or adenosine kinase (AK); both are believed to be located primarily in the cytoplasm (Sciotti & van Wylen, 1993; Geiger, Parkinson & Kowaluk, 1997) . ADA (EC 3.5.4.4) is a 36 kDa protein that forms a 280 kDa polypeptide via its binding to ADA-binding proteins (Geiger, Padua & Nagy, 1991) . ADA catalyzes the formation of inosine from adenosine. It is heterogeneously distributed among tissues, with its activity highest during development. AK (EC 2.7.1.20) is a monomeric protein of molecular weight 38-56 kDa, and is widely distributed throughout the body. It catalyzes the phosphorylation of adenosine to 5%-AMP. This reaction is inhibited by the specific inhibitor 5-iodotubercidin (Phillis & Smith-Barbour, 1993) . AK cDNA has been recently cloned (Spychala, Datta, Takabayashi, Datta, Fox, Gribbin et al., 1996) . Since adenosine can inhibit AK when the intracellular concentration of adenosine is only slightly greater than the apparent Km for the enzyme, it has been proposed that two adenosine-binding sites exist on AK. One is a high-affinity catalytic site, the other a low-affinity inhibitory site that may require the binding of Mg 2 + . The kinetic mechanisms of AK require further elucidation (Geiger et al., 1997) .
Five types of adenosine transporters exist, classified according to their sensitivity to the transport inhibitor NBTI. Multiple transport processes may coexist in the same cell. Some of these transport processes are Na + -dependent. Adenosine transporters may favor influx or efflux and are thought to be bidirectional (Geiger et al., 1997) . Following adenosine's conversion to inosine, the final catabolic steps involve the enzymes xanthine dehydrogenase (XDH, EC 1.1.1.204) or oxidase (XO, EC 1.1.3.22) (Amaya, Yamazaki, Sato, Noda, Nishino & Nishino, 1990) . Xanthine dehydrogenase catalyzes the oxidation of hypoxanthine to xanthine and of xanthine to uric acid, resulting also in the reduction of NAD to NADH. XDH is a molybdenum iron-sulfur flavin hydrolase that exists as a dimer with a molecular weight of approximately 150 kDa (Poss, Huecksteadt, Panus, Freeman & Hoidal, 1996) . XDH may be converted through reversible sulfhydryl oxidation or irreversible proteolytic modification to the oxygen-dependent enzyme XO. XO generates superoxide radical (O 2 − ) and hydrogen peroxide (H 2 O 2 ), which are damaging to cells. Endothelial cells are key sources of XO (Terada, Willingham, Rosandich, Leff, Kindt and Repine, 1991; Terada, Guidot, Leff, Willingham, Hanley, Piermattei et al., 1992) , the formation and activity of which is stimulated by ischemia and reperfusion.
Measurement of retinal adenosine concentration
The accurate detection of adenosine is important in experiments that examine the impact of alterations in adenosine concentration on physiological parameters such as blood flow or electrophysiological function. One of the major difficulties in analyzing tissue purine concentrations is that samples must be taken rapidly enough to ensure that metabolic enzyme activity does not continue during tissue processing and thus falsely alter the adenosine concentration, either by continued adenosine formation or metabolism (Fredholm, 1987) . Frozen tongs (Berne, Rubio & Curnish, 1974) or in situ freezing (Rehncrona, Siesjo & Westerberg, 1978) were used to sample cerebral cortical tissue, but artifacts due to tissue damage may increase adenosine concentration (Winn, Rubio & Berne, 1981) . The freeze-blow method (Winn et al., 1981) allowed accurate sampling of adenosine concentration in deeper portions of the cerebral cortex. Another technique measures tissue adenosine concentration after subjecting animals to rapid microwave irradiation (Phillis & O'Regan, 1996) . This method is highly effective, but requires a costly apparatus not universally available. The disadvantage of all tissue sampling methods is that intracellular and extracellular adenosine concentrations cannot be differentiated, but relative changes in total adenosine concentration may be measured.
Microdialysis or sampling from cortical cup preparations has been used to estimate cerebral extracellular adenosine concentration (Headrick, Bendall, Faden & Vink, 1994; Phillis, Smith-Barbour, O'Regan & Perkins, 1994) , but neither of these methods seems practical for adenosine measurement in the retina. Recently, concentrations of adenosine and its metabolites were effectively measured using high performance liquid chromatography (HPLC) from the intact in vivo rat retina (Roth, Osinski, Park, Ostwald & Moshfeghi, 1996) . Quantitative, accurate, and reproducible measurements of the small concentrations were made possible through the use of internal standards. This technique requires in situ freezing of the eyes, after which the retina is separated from the other eye tissues and processed. Unlike in brain, in situ freezing is highly effective for the retina because of the small size of the eye and the presence of the aqueous vitreous in immediate proximity to the retina. The main disadvantages are that only one measurement can be performed per animal, and adenosine content of the retina and choroid cannot be analyzed separately. In addition, both extracellular and intracellular adenosine are measured. However, the vitreous may be sampled and analyzed to provide data on concentrations of purine metabolites in extracellular fluid. These measurements have been performed in the in vivo intact rat retina subjected to ischemia and reperfusion for varying periods of time, and the time course of changes in purine concentration during and immediately after ischemia has been elucidated (Roth, Park, Sikorski, Osinski & Chan, 1997a; Roth, Rosenbaum, Osinski, Park, Toledano, Li et al., 1997b) .
Changes in adenosine concentration during ischemia and reperfusion
We examined the time course of changes in the concentration of adenosine and its metabolites in the rat retina during ischemia-reperfusion using HPLC (Roth et al., 1997a,b) . The changes in purine concentration during ischemia followed a time course consistent with the formation and subsequent metabolism of adenosine, i.e., significant increases in adenosine concentration were recorded within 5 min after the onset of ischemia. In the vitreous, the concentrations of inosine and hypoxanthine were not elevated until 60 min of ischemia, probably reflecting a slow diffusion of these substances from the retina into the overlying vitreous (Roth et al., 1997b) . All increases in purine concentration lasted through 120 min of ischemia, the longest timepoint we tested. Increases in adenosine concentration during ischemia plateaued after 30 min, suggesting that the production of adenosine is a fairly short-lived response to ischemia. Conversely, the ongoing increase in the concentrations of adenosine metabolites occurring after 30 min of continuous ischemia indicate that prolonged ischemia activates enzymatic pathways catalyzing the conversion of adenosine to several downstream metabolites.
The concentrations of adenosine and its metabolites in the rat retina-choroid were also measured during reperfusion following both short (10 min) and long (60 min) periods of ischemia (Roth et al., 1997a) . Changes in the concentration of adenosine and its metabolites were approximately 4-fold greater in magnitude following the more prolonged ischemia. In the latter instance, adenosine, inosine, and hypoxanthine concentrations remained elevated through the initial 30 min of reperfusion. The peak in xanthine concentration was delayed (30 min) in comparison to adenosine (5 and 10 min), and elevations in xanthine levels were sustained to 60 min of reperfusion.
In summary, these data indicate that retinal ischemia results in a rapid increase in adenosine and its purine metabolites, and that the concentrations achieved during ischemia are proportional to the duration of ischemia. The increase in adenosine concentration that occurs during early reperfusion after prolonged ischemia correlates well with the finding that adenosine mediates post-ischemic hyperemia (Ostwald, Park, Toledano & Roth, 1997) . During prolonged ischemia, and in the reperfusion period after ischemia, delayed increases in adenosine metabolites may paradoxically damage the retina as a result of superoxide radical formation from the XO-mediated conversion of hypoxanthine to xanthine and of xanthine to uric acid (Roth et al., 1997a) .
Functional effects of adenosine in the retina
In 6i6o effects of A1 and A2 receptor stimulation in retinal ischemia
Recent studies have shown that adenosine plays an extremely important functional role in the retina's response to ischemia. In rats subjected to retinal ischemia by elevation of intraocular pressure, intravitreal injection of adenosine deaminase nearly eliminated the postischemic recovery of the electroretinogram (ERG) b-wave. In contrast, the adenosine deaminase inhibitor erythro-9-(2hydroxy-3-nonyl)adenine hydrochloride (EHNA) significantly enhanced the rate of b-wave recovery (Larsen & Osborne, 1996) , and prevented ischemia-induced thinning of retinal cell layers (Fig. 4) . These authors suggested that the protective effect of EHNA was mediated via adenosine's binding to the A1 receptor, because systemic injection of the A1 receptor agonist R-PIA also enhanced recovery. The 45 min of ischemia used in this study was not a severe ischemia, because of inconsistent histological damage to the retina and a 54% recovery of the ERG b-wave by 3 days after ischemia. Nonetheless, the results suggest that increases in adenosine concentration during and immediately after ischemia (Roth et al., 1997a,b) may serve in an endogenous protective capacity.
However, this conclusion may actually depend on the relative stimulation of different adenosine receptors and the severity of ischemia. To examine the impact of severity of ischemia, rats were subjected to ischemia for 5, 30, or 60 min by ligation of the central retinal artery; the recovery of the ERG a-and b-waves was followed for up to 7 days later, and retinas were examined histologically on the 7th post-ischemic day. Following 5 min of ischemia, there was complete recovery of the aand b-waves and no evidence of histological damage. In contrast, after 60 min of ischemia there was B 15% recovery of electrical function, and at least a 50% reduction in retinal cell layer thickness and cell counts . However, 30 min of ischemia resulted in injury of intermediate severity, leading to 45-50% recovery of the a-and b-waves, but no histological damage. Thus, the effects of adenosine receptor blockade in the rat model could be examined under conditions of differing ischemic durations (Li, Rosenbaum, Jennings, Maxwell & Roth, 1999) .
Using electrophysiological and histological approaches, we studied the roles of the A1 and A2a receptors in this graded ischemia model (Li et al., 1999) . The A1 receptor selective antagonist DPCPX given prior to 5 or 30 min of ischemia decreased the recovery of the a-and b-waves by \ 50% within the first 2 h after ischemia ended, with the effect persisting up to 7 days later in the rats subjected to 30 min of ischemia. DPCPX given prior to 60 min of ischemia had no effect upon a-and b-wave recovery, and there were no significant differences in histological findings in vehicle-versus DPCPX-injected rats subjected to severe (60 min) ischemia. The A2a antagonist CSC, given prior to 5 min of ischemia, decreased the recovery of the a-and b-waves in the first 120 min after ischemia, but by day 1 after ischemia there was no difference from vehicle-injected animals. CSC given prior to 30 or 60 min of ischemia resulted in nearly complete post-is- Fig. 4 . Treatment of rat retina with the adenosine A1 receptor agonist R-N 6 -(2-phenylisopropyl) adenosine (R-PIA) or the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride (EHNA) prior to ischemia attenuates the loss of thickness of the inner plexiform and inner nuclear layers. Retinas were sectioned 1 mm thick, and stained with toluidine blue-Azure II, then examined using light microscopy. Results are expressed as mean 9 S.E.M. ** PB 0.01, and *PB 0.05 in comparison to the control, non-ischemic retinas. Redrawn with permission of the Association for Research in Vision and Ophthalmology from Larsen and Osborne (1996) . . Representative photomicrographs (100 × ) demonstrating the effects on retinal structure of antagonism of adenosine A1 or A2a receptors prior to 60 min of ischemia. Systemic administration of CSC 1 mg/kg prior to 60 min of ischemia in rats resulted in nearly complete preservation of retinal structure compared to that present in vehicle-treated animals. In rats treated with DPCPX 4.5 mg/kg prior to ischemia there was greater loss of the ganglion cells compared to vehicle treated rats. Retinas were collected from rats 7 days after ischemia, sectioned 1 mm thick, and stained with toluidine blue. Symbols: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer. Reproduced with permission of Acedemic Press, Inc., from Li et al. (1999) . chemic recovery up to 7 days after ischemia. Moreover, retinas treated with CSC prior to 60 min of ischemia demonstrated profound structural protection in comparison to vehicle-treated controls (Fig. 5) . Neither A1 nor A2a receptor blockade produced any significant effect upon the non-ischemic retina.
It appears from these data that activation of A1 adenosine receptors during and following retinal ischemia promotes neuroprotective effects, whereas activation of A2a adenosine receptors promotes ischemic injury. These results are in agreement with previous studies in cerebral ischemia (Phillis, 1995) wherein exogenous administration of A1 receptor agonists enhanced recovery after short-term ischemia. Why the A1 receptor affords protection only after brief periods of ischemia, but not when ischemia is more prolonged, could be the result of a down-regulation of the A1 receptor that occurs after more extended periods of ischemia (Lee, Tetzlaff & Kreutzberg, 1986; Rudolphi & Schubert, 1997) . Conversely, post-ischemic upregulation of the A2a receptor, possibly during the time of A1 down-regulation, has been suggested from studies of cerebral ischemia in the gerbil (von Lubitz, Carter, Beenhakker, Lin & Jacobson, 1995) . Precisely how A2a receptor blockade might be protective is not known. Among the possible mechanisms are alterations in blood flow (Gidday & Park, 1993a) , decreased release of excitatory amino acids (Sebastiao & Ribeiro, 1996) , or changes in expression of other intercellular signalling molecules such as VEGF (Takagi et al., 1996a) .
In summary, these studies show that the involvement of adenosine in retinal ischemia is not a simple matter of increases in adenosine concentration being acutely protective; rather, they suggest a complex interaction of adenosine effects at different receptor subtypes. It appears that enhancing A1 receptor activity, and decreasing A2a receptor activity, are protective. The mechanisms activated by adenosine's stimulation of each receptor subtype have not yet been identified.
Significance of adenosine metabolism
As discussed above, increases in the concentrations of adenosine may not necessarily protect the retina from ischemic injury. In addition to the differing effects of A1 and A2 receptor stimulation, of considerable importance in retinal ischemic outcome are the functional consequences of the formation of adenosine metabolites. These metabolites could be injurious to the retina, since the metabolism of hypoxanthine and xanthine may increase oxidative stress. The impact of adenosine metabolism on the outcome after retinal ischemia has been examined by pharmacological inhibition of these metabolic pathways. Treatment of isolated perfused cat eyes with allopurinol, an inhibitor of XO, reduced the damage that resulted from ischemia (Peachey, Green & Ripps, 1993) .
Post-ischemic electroretinographic recovery was also significantly increased in this model following allopurinol pretreatment. These results suggest that during reoxygenation, the action of XO produces superoxide radical which impairs functional recovery of the retina. However, allopurinol at the doses used in this study could have served as a free radical-scavenger itself (Augustin, Boker, Blumenroder, Lutz & Spitznas, 1994) . Thus, this beneficial effect may be a result of a combination of XO inhibition as well as the direct quenching of superoxide radical.
The effect of inhibition of XO in the intact rat retina subjected to ischemia for 60 min was recently studied (Roth et al., 1997a) . The allopurinol metabolite oxypurinol (40-80 mg/kg), another inhibitor of XO, caused a dose-dependent improvement in recovery of the electroretinogram b-wave in the rat up to 7 days following 60 min of ischemia. Taken together with the significant, time-dependent increases in hypoxanthine and xanthine concentrations during ischemia and reperfusion (Roth et al., 1997a) , these results indicate that the retina can be damaged by the formation of adenosine metabolites, and that treatment of ischemic disorders in the retina might be amenable to intervention with xanthine oxidase inhibition, provided effective post-ischemic treatment with xanthine oxidase inhibitors can be demonstrated experimentally. The cell types producing superoxide via the XO pathways, and those protected by XO inhibition have not yet been identified.
Adenosine in diabetic and other ischemic retinopathies
Chronic retinal ischemia is a common mechanism that leads to blindness in conditions such as diabetic retinopathy and retinopathy of prematurity. Longstanding reductions in blood flow and oxygen delivery typically lead to compensatory neovascularization. While there are many ocular angiogenic growth factors, a flurry of recent studies suggest that VEGF is a major mediator of this neovascular process (Miller et al., 1997) . VEGF is an endothelial mitogen, angiogenic protein, and a potent vasopermeability factor. VEGF is secreted by cells and binds to endothelial fms-like tyrosine kinase (Flt) and kinase insert domain-containing (KDR) receptors (Aiello, Pierce, Foley, Takagi, Chen, Riddle, Ferrara et al., 1995) .
A number of studies suggest that adenosine, by virtue of its ability to promote VEGF formation, is a key trigger in the growth of retinal vessels and the pathogenesis of neovascularization. Adenosine increased VEGF-induced proliferation of canine retinal microvascular endothelial cells, a response attenuated by A2a receptor antagonists (Lutty, Mathews, Merges & McLeod, 1998) . A series of studies in cultured bovine retinal endothelial cells (Takagi et al., 1996a,b) revealed the following: Prolonged hypoxia increased VEGF binding. The adenosine A1 receptor agonist CPA had no effect upon KDR receptor mRNA expression or VEGF expression at low concentrations, but at higher concentrations where it interacts with the A2 receptor, CPA decreased KDR mRNA levels to 30% of control and promoted VEGF expression (Fig. 6) . DPMA, an adenosine A2 receptor agonist, decreased KDR mRNA in a dose-dependent manner while CSC, the A2a receptor antagonist, attenuated the dose-and time-dependent reduction in KDR gene expression by hypoxia. The A2 agonists DPMA, NECA, and CGS21680 each increased VEGF mRNA approximately 2-fold. Administration of adenosine deaminase reduced hypoxic expression of VEGF mRNA by 37%, while the A2a antagonist CSC resulted in a 68% decrease. VEGF protein increased nearly 5-fold during hypoxia in cells exposed to NECA, an effect completely inhibited by CSC. From these in vitro studies, it appears that the induction of VEGF expression during hypoxia largely results from an increase in adenosine concentration and its binding to the A2a receptor. Although adenosine acts to reduce the expression of the VEGF receptor KDR via an adenosine A2 receptor-mediated effect during acute hypoxia, prolonged hypoxia results in an opposite effect, which may in fact parallel the clinical manifestations of neovascularization after chronic retinal ischemia. Fig. 6 . Stimulation of the adenosine A2a, but not the A1 receptor, increases expression of VEGF. Increasing concentrations of the adenosine A1 receptor agonist CPA or the A2a receptor agonist CGS21680 were administered to normoxic bovine retinal pericytes in vitro. VEGF expression was quantitated as a percent of control (Y-axis) by Northern blot analysis. The adenosine A2a antagonist CSC, but not the A1 antagonist DPCPX, decreased expression of VEGF (not shown). The data are expressed as mean 9 S.E.M. * PB 0.05, ** P B0.01, *** PB0.001, and ‡ P= 0.005 versus control (i.e., concentration of agonist =0). Redrawn with permission of the Association for Research in Vision and Ophthalmology from Takagi et al. (1996b) .
In summary, adenosine participates importantly in the neovascular response to hypoxia in the retina. VEGF action is important in the neovascularization response, and VEGF formation and VEGF receptors are modulated by adenosine. An increase in adenosine concentration, acting through its A2 receptor, results in an increase in the expression of VEGF and a decrease in the KDR VEGF receptor. After prolonged hypoxia, although the number of VEGF receptors is decreased, the binding capacity for VEGF is increased, thereby facilitating the neovascular response.
Adenosine and retinal blood flow
Adenosine has been shown to act as a vasodilator in heart, skeletal muscle, and brain (Phillis, 1989) . A significant role for adenosine in the regulation of retinal blood flow in a variety of species has been forthcoming from studies of vascular effects of exogenous adenosine, adenosine uptake inhibitors, and adenosine receptor antagonists. The reader is cautioned that these studies be interpreted in view of the route of delivery of the pharmacologic agents tested, the species studied, the method used to estimate retinal blood flow, and the physiologic or even pathophysiologic relevance of the doses of agents used. Among the first studies of adenosine's vascular effects in the eye were those performed by Braunagel, Xaio and Chiou (1988) . Intravitreal injection of adenosine or the adenosine uptake inhibitor dipyridamole in rabbits increased retinal blood flow as measured by laser Doppler flowmetry. The dipyridamole-induced increase in blood flow was caused by an increase in endogenous adenosine concentration since concomitant administration of the adenosine receptor antagonist 8-phenyltheophylline returned blood flow to control levels. Using radiolabelled microspheres, these investigators also demonstrated that adenosine alone, dipyridamole alone, and adenosine together with dipyridamole caused a significant increase in blood flow to the retina, choroid, iris, and ciliary body, again blocked by 8-phenyltheophylline. Comparisons of the dose-response in each ocular tissue revealed that the retina was the most sensitive to dipyridamole.
Similar conclusions about adenosine's possible role in the regulation of retinal blood flow were inferred from intravitreal injections of extremely large doses of adenosine and its agonists in rabbits, marmosets, and cats . In these studies, blood flow was estimated indirectly from changes in the diameter of large retinal veins, imaged by fundus photography 6 and 24 h after intravitreal injection. Adenosine and dipyridamole were effective dilators (40% increase in diameter), with dilation still present 6 h after midvitreal injection of these compounds; by 24 h, these dilatative effects subsided. Injection of a potent adenosine receptor antagonist, BW-A1433U, reversed this effect, confirming that adenosine was in fact responsible for the venous vasodilation. NECA, a nonspecific adenosine receptor agonist with some selectivity for A2 adenosine receptors, caused a similar degree of dilation, but its effect lasted for at least 24 h. Although the vasodilatory actions of adenosine are generally short-lived, the long-lasting effects of NECA were likely the result of the high concentrations of NECA injected, the slow diffusion of NECA through the vitreous, the tight binding of NECA to its receptor, and the resistance of NECA to inactivation by adenosine deaminase. The authors reported that adenosine and dipyridamole occasionally caused small subhyaloid and intraretinal hemorrhages in addition to vasodilation, and concluded that adenosine might alter the integrity of the blood-retinal barrier. In a separate study, the same authors used vitreous fluorophotometry to measure fluorescein leakage in rabbits, and showed that the increase in blood flow resulting from intravitreal injection of adenosine or its receptor agonists was associated with breakdown of the blood-retinal barrier . Overall, the pathophysiologic relevance of these blood flow and leakage results must be regarded as questionable, however, because of the extremely high, non-physiological, and combined doses of adenosine, dipyridamole, and adenosine agonists (Gidday & Park, 1993b) .
Intravitreal microsuffusions of adenosine and several of its receptor-specific agonists onto the retinal arteriolar resistance vessels of the piglet using a microscopeguided intravitreal cannula revealed a dilation dose-response profile consistent with adenosine actions at A2 receptors (Gidday & Park, 1993a) . Intravitreal injections of the adenosine transport inhibitor NBTI and the adenosine kinase inhibitor iodotubercidin both resulted in rapid and long-lasting increases in arteriolar diameters. The response to the former was blocked by co-infusion of the A2 receptor antagonist DPMX. These latter results indicated that potentiation of endogenous retinal adenosine concentration by several different pharmacologic strategies can promote vasodilation and increase retinal blood flow, most likely via an A2 receptor-mediated effect.
Although results of cerebral vascular studies are consistent with adenosine action at vascular A2 adenosine receptors positively coupled to adenylate cyclase, with resultant formation of cAMP, studies in the piglet retina did not support this hypothesis . Rather, we found that the adenosine-induced hyperemia, as measured by fluorescein angiography following intravitreal microsuffusions of adenosine, was attenuated in a dose-dependent manner by glibenclamide, a K + ATP channel antagonist. This result indicates that K + ATP channels mediate adenosine's vasodilatative effect. As predicted, intravitreal injection of cromakalim, a K + ATP channel opener, increased retinal blood flow significantly, indicative of a general role for K + ATP channels in the regulation of retinal blood flow. The effect of intravascular adenosine on blood flow in the optic nerve head, retina, and choroid was examined in cats using laser Doppler flowmetry and velocimetry along with fundus photography (Portellos, Riva, Cranstoun, Petrig & Brucker, 1995) . Intravenous infusions of adenosine increased choroidal blood flow by 60%, but retinal and optic nerve head blood flows were not significantly altered. It would seem that peripherally administered adenosine can leak through choroidal capillary fenestrae and cause vasodilation of this vascular bed, but cannot penetrate the retinal and optic nerve blood vessels to reach what are presumably abluminal adenosine receptors on the vascular smooth muscle. This asymmetry was confirmed in vitro, wherein extravascular adenosine caused dose-dependent relaxations of isolated perfused retinal arterioles, but equal concentrations of intravascular adenosine were ineffective as a vasodilatory stimulus (Alder, Su, Yu, Cringle & Yu, 1996) . Thus, intravitreal administration of adenosine and its agonists may more suitably mimic the actual conditions under which adenosine is released from surrounding retinal neurons than systemically administered, intravascular adenosine.
The same conclusion might be applied to adenosine antagonists, although the high lipophilicity of many xanthine-based adenosine receptor antagonists will result in penetration of the blood-retinal barrier following systemic administration, as reflected in the ability of systemically administered caffeine to reduce the velocity of leukocytes measured by the blue entopic technique in humans (Lofti & Grunwald, 1991) . While the results of the latter study suggest a tonic vasodilatative role for adenosine in the retinal microcirculation, results from studies in both piglet (Gidday & Park, 1993b) and cat (Ostwald et al., 1997) using intravitreal injections of adenosine receptor antagonists do not support the concept that ongoing adenosine formation contributes to the maintenance of retinal blood flow under resting conditions. This important hemodynamic issue will likely have ramifications for therapies directed at the ischemic retinal vasculature, but its resolution will require additional studies.
Results of a recent investigation suggest that adenosine-induced increases in retinal blood flow may occur, in part, by relaxation of retinal pericytes (Matsugi, Chen & Anderson, 1997) . Cultured pericytes relaxed in the presence of adenosine in a dose-dependent manner. The relaxation began within 1 min of exposure to adenosine, with a 50% effective concentration of approximately 3×10 − 7 M, similar to levels of adenosine that would be present in the peri-vascular spaces in vivo. The response to adenosine was reversible 10 min after its removal from the media. 8-Phenyltheophylline, a nonselective adenosine receptor antagonist, inhibited adenosine-induced pericyte relaxation. Since the A1-specific receptor antagonist DPCPX had no effect on relaxation, while CP-66713, a selective A2 receptor antagonist, inhibited adenosine-induced relaxation, it appears that adenosine relaxes retinal pericytes by an A2 receptor-mediated mechanism.
In summary, endogenous adenosine is an important regulator of retinal blood flow in response to changes in substrate delivery by virtue of its ability to dilate retinal arterioles and venules. Thus, one might predict that these vascular effects of adenosine would be beneficial in the setting of ischemia to promote increases in tissue blood flow during and after a period of substrate deprivation. This hypothesis is supported by evidence from studies outlined below.
Blood flow and adenosine: effects of ischemia, hypoxia, and hypoglycemia
Because adenosine is an important component of the retinal response to oxygen and substrate deprivation, several studies have examined its role in the regulation of retinal blood flow under pathological conditions. These experiments have been performed in several different mammalian species.
Blood flow in the retina and choroid of cats was measured using radioactive microspheres after 60 min of ischemia induced by elevation of intraocular pressure (Roth & Pietrzyk, 1994) . During ischemia, retinal blood flow (RBF) was reduced to 6%, and choroidal (CoBF) to 0.6%, of baseline. Immediately after the end of ischemia, there were profound alterations in blood flow. From 5 to 15 min after ischemia ended, RBF increased to 200% of baseline and CoBF to 108% of baseline, indicative of what is termed a reactive hyperemic response. By 60 min, both flows had returned to nearly baseline levels. In two subsequent experiments, the adenosine receptor antagonist 8-SPT profoundly attenuated this post-ischemic hyperemia in retina but had little effect on CoBF (Roth, 1995; Ostwald et al., 1997) .
Other vasoactive substances such as nitric oxide (NO) have since been found to play a role in this reactive hyperemia as well. Whereas the adenosine receptor antagonist 8-SPT alone attenuated the hyperemic response, and nitric oxide synthase (NOS) inhibition alone had little effect on the hyperemic response, NOS inhibition in combination with the adenosine receptor antagonist resulted in the reappearance of the reactive hyperemia (Ostwald et al., 1997) . The nature of this apparent interaction between adenosine and NO is still unclear. It is possible that NOS inhibition may have increased retinal adenosine concentration to an extent sufficient to overcome competitive adenosine receptor blockade with SPT. This speculation is supported by the findings that reactive hyperemia in the isolated guinea pig heart was associated with an increase in adenosine and NO concentrations and that inhibition of NOS by L-NAME significantly increased adenosine release under basal and post-ischemic conditions (Kostic & Schrader, 1992) .
After the acute compensatory hyperemic response to a period of retinal ischemia, retinal blood flow may fall significantly below baseline levels in what has been termed in cerebral ischemia a delayed hypoperfusion response. Delayed changes in blood flow have been documented in piglets at 1 -2 h following the combination of severe hypoxia, hypotension, bradycardia, and acidosis secondary to a short period of asphyxia (Gidday & Zhu, 1998) , and also following periods of complete ischemia (central retinal artery ligation) exceeding 30 min in the rat retina (Lin & Roth, 1998) . It is thought that this flow reduction adds additional insult to an already ischemic tissue. Some caution is called for in this interpretation because simultaneous measures of retinal blood flow and metabolic rate have not yet been undertaken to determine whether this response may represent ongoing flow-metabolism coupling. Nonetheless, intravitreal administration of NBTI, an adenosine transport inhibitor that potentiates extracellular adenosine concentrations, completely reversed this response in the piglet (Gidday & Zhu, 1998) (Fig. 7) , indicating that the adenosine vascular signal transduction mechanism is intact following ischemia. These results also identify a possible therapeutic strategy to support tissue perfusion following ischemia, namely, to attempt to increase tissue adenosine concentration.
Retinal arterioles of the piglet dilate robustly in response to reductions in oxygen delivery by systemic hypoxia (P a O 2 = 259 1 mmHg) or to the reductions in oxygen and glucose supply induced by systemic hypotension (MABP=41 9 3 mmHg). The latter response is autoregulatory by definition. Because intravitreal microsuffusion of 8SPT, a non-specific adenosine receptor antagonist, significantly attenuated each of these responses, adenosine was implicated as responsible for mediating a large part of these responses (Gidday & Park, 1993a) . Intravitreal microsuffusion of NBTI to potentiate extracellular adenosine concentrations significantly enhanced vasodilatation during hypotension, adding further support to the hypothesis that adenosine is important in mediating autoregulatory adjustments in retinal arteriolar tone.
As in hypoxia, the retina reacts to hypoglycemia with a compensatory increase in blood flow . We used fluorescein videoangiography to measure blood flow in newborn pigs rendered hypoglycemic by insulin injection. Acute hypoglycemia (blood glucose = 1991 mg/dl) doubled RBF secondary to a dilation of arterioles and a decrease in arteriovenous transit time. Intravenous pretreatment with the adenosine receptor antagonist 8-phenyltheophylline significantly at- Fig. 7 . Effect of extracellular adenosine potentiation with the transport inhibitor NBTI on post-asphyxic retinal blood flow in piglets. Changes in retinal blood flow (normalized to pre-asphyxic baseline values, mean9S.E.M.) were measured by videofluorescein angiography at 1 and 2 h after 9 min of asphyxia in a vehicle-treated control animal group (n = 6; open bars) and a group (n =6; shaded bars) treated with 0.1 nmol of NBTI administered as an intravitreal microsuffusion (50 ml of a 2 mM solution) over the retinal vessels under videomicroscopic observation. Intravitreal NBTI reversed the postasphyxic hypoperfusion into a relative hyperemia. (* PB 0.05 versus preasphyxic baseline; † P B0.05 versus control group at same postasphyxic time). Reprinted with permission of Oxford Press, Inc., from Gidday et al. (1998). tenuated the hypoglycemia-induced retinal hyperemia, indicating that adenosine is critical to the elicitation of this response as well (Fig. 8) . Hypoglycemia is likely to promote increases in adenosine formation because of limired available substrate and the consequent decrease in ATP concentration.
In summary, adenosine formation in response to hypoxia, hypoglycemia, and ischemia affects retinal blood flow. Adenosine's ability to increase blood flow in a compensatory manner in response to either reductions in oxygen and/or glucose supply reflects its status as an endogenous retaliatory metabolite (Perez-Pinzon, Lutz, Sick & Rosenthal, 1993) . Exogenous therapies aimed at increasing adenosine concentration may improve tissue perfusion following ischemia.
Ischemic preconditioning
Ischemic preconditioning (IPC) is an intriguing phenomenon in which a state of resistance to ischemic injury is produced by a previous, brief, non-damaging period of ischemia. IPC was recently demonstrated to be operative in the retina . Understanding the endogenous mechanisms by which IPC protects the retina can give insight into possible preven-tive and/or treatment options for retinal ischemic disorders.
When 5 min of ischemia (IPC) was followed 24 or 72 h later by 60 min of ischemia in rats, complete functional recovery (by electroretinography) occurred within 24 h, and no histological damage was present 7 days after ischemia, a dramatic effect that has not been seen to any similar extent following any type of exogenous pharmacological manipulation. These effects are time-dependent; separation of the 5 min IPC stimulus and 60 min of ischemia by either 1 or 168 h resulted in no protection against the effects of ischemia. The protective effect of IPC was attenuated completely by inhibition of protein synthesis.
Adenosine appears to be required for IPC-mediated protection in this model (Li & Roth, in press ). Pretreatment with the adenosine A1 receptor antagonist DPCPX prior to IPC attenuated recovery from 60 min of ischemia in a dose-dependent manner. The adenosine A2a receptor antagonist CSC, which is 25-fold selective for the A2a receptor, partially attenuated the effects of preconditioning, but only at the highest dose used (1.0 mg/kg). Intravitreal injection of adenosine receptor agonists produced a partial mimicking of the IPC effect. The pathways responsible for preconditioning protection probably involve a complex series of other as yet incompletely described mediators.
Conclusions
Adenosine mediates vital changes in oxygen delivery to the retina when blood flow and substrate delivery are altered, as for example during hypoxia, ischemia, or hypoglycemia. Under these conditions, adenosine appears to be one of the major mediators. Large changes in adenosine concentration during both ischemia and during the ensuing reperfusion period affect function, mediated by both adenosine A1 and A2a receptors, which can produce opposing effects. Under some circumstances, particularly after prolonged ischemia, increases in adenosine concentration could be injurious, due to the formation of superoxide radicals following adenosine's conversion to xanthine and uric acid. Moreover, in vitro studies suggest that chronic ischemia and hypoxia stimulate increases in VEGF, a mediator of neovascularization, in an adenosine-dependent manner. The induction of a remarkably tolerant state to ischemic injury (ischemic preconditioning) is mediated by adenosine, suggesting a novel means to further explore the role of adenosine in ischemic protection of the retina. Overall, these findings indicate that adenosine is one of the major components of the retina's response to acute or chronic ischemia. As such, the continued investigation of the involvement of adenosine in the retina may lead to important clinical applications of adenosine-based therapies in retinal ischemic disorders. Fig. 8 . Effect of the nonspecific adenosine receptor antagonist 8-phenyltheophylline (8-PT; 10 mg/kg i.v.) on the compensatory changes in retinal blood flow in piglets in response to hypoglycemia induced by insulin (25 IU/kg, i.v.) . Retinal blood flow (mean 9 S.E.M.) was determined by videofluorescein angiography and was normalized to normoglycemic baseline flows in each animal group (mean 9 S.E.M.). The increase in retinal blood flow during the initial 30 min of hypoglycemia (n = 5; blood glucose = 209 1 mg/dl; ) was significantly attenuated in animals pretreated with 8-PT 15 min before hypoglycemia (n = 5; blood glucose = 199 3 mg/dl; ). (* PB0.05 versus normoglycemic baseline; † PB 0.05 versus control group at same time of hypoglycemia). Reprinted with permission of the Association for Research in Vision and Ophthalmology, from Zhu and Gidday (1996) .
